


# PRODUCT INFORMATION



## Moexiprilat

Item No. 38047

**CAS Registry No.:** 103775-14-0  
**Formal Name:** (3S)-2-[(2S)-2-[[[(1S)-1-carboxy-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid  
**Synonym:** RS 10029  
**MF:** C<sub>25</sub>H<sub>30</sub>N<sub>2</sub>O<sub>7</sub>  
**FW:** 470.5  
**Purity:** ≥95%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Moexiprilat is supplied as a solid. A stock solution may be made by dissolving the moexiprilat in the solvent of choice, which should be purged with an inert gas. Moexiprilat is soluble in methanol and DMSO.

### Description

Moexiprilat is an inhibitor of angiotensin-converting enzyme (ACE; IC<sub>50</sub> = 2.1 nM) and an active metabolite of the prodrug moexipril (Item No. 21255).<sup>1</sup> It is formed from moexipril *in vivo* by side chain ester hydrolysis.<sup>2</sup> Moexiprilat (10 nM) prevents the estrone- or angiotensin II-stimulated proliferation of primary neonatal rat cardiac fibroblasts.<sup>3</sup> It reduces mean arterial blood pressure and increases the levels of atrial natriuretic peptide, a marker of hypertension, in ovariectomized mice when administered at a dose of 50 mg/kg per day.<sup>4</sup>

### References

1. Edling, O., Bao, G., Feelisch, M., *et al.* Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: Pharmacological characterization and comparison with enalapril. *J. Pharmacol. Exp. Ther.* **275**(2), 854-863 (1995).
2. Cameron, R.T., Coleman, R.G., Day, J.P., *et al.* Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4). *Biochem. Pharmacol.* **85**(9), 1297-1305 (2013).
3. Grohé, C., Kahlert, S., Löbber, K., *et al.* Angiotensin converting enzyme inhibition modulates cardiac fibroblast growth. *J. Hypertens.* **16**(3), 377-384 (1998).
4. van Eickels, M., Schreckenber, R., Doevendans, P.A., *et al.* The influence of oestrogen-deficiency and ACE inhibition on the progression of myocardial hypertrophy in spontaneously hypertensive rats. *Eur. J. Heart Fail.* **7**(7), 1079-1084 (2005).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 07/05/2023

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM